P524: PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML (KB-LANRA 1001)
E. M. Stein,
A. Patel,
L. C. Michaelis,
G. Schiller,
R. Swords,
L. A. Carvajal,
G. Bray,
J. DiMartino,
M. Y. Levy
Affiliations
E. M. Stein
1 Memorial Sloan Kettering Cancer Center, New York
A. Patel
2 The University of Chicago Medical Center, Chicago
L. C. Michaelis
3 Medical College of Wisconsin, Milwaukee
G. Schiller
4 University of California Los Angeles (UCLA), Los Angeles
R. Swords
5 Oregon Health and Science University, Portland
L. A. Carvajal
6 Kronos Bio, Inc., San Mateo
G. Bray
6 Kronos Bio, Inc., San Mateo
J. DiMartino
6 Kronos Bio, Inc., San Mateo
M. Y. Levy
7 Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, United States of America
